Similarly, the alpha-specific PI3K inhibitor alpelisib showed promising activity in combination with albumin-bound paclitaxel in patients with metastatic HER2-negative breast cancer, most (30/43, 70%) of whom had received at most one prior line of chemotherapy in the metastatic setting [33]. The gene discussed is PIK3CB; the disease is breast carcinoma.